An interventional study of Vivomixx and Placebo in Autism Spectrum Disorder, sponsored by University College, London. Completed at 1 site in United Kingdom. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by University College, London · Not applicable, Interventional, and Treatment
The purpose of this study is to assess the effects of 3 months supplementation with the multi strain probiotic Vivomixx on the overall function, aberrant behaviours and frequency of gastrointestinal symptoms in children with Autism Spectrum Disorders and co-morbid gastrointestinal symptoms.
The investigators will also assess the effect of the intervention on parenting stress.
A further issue will be to identify any predictors of response to the probiotic.
Finally, the investigators will assess whether there is an association between altered behaviour and altered gut function in users of Vivomixx.
Potential trial participants will be recruited via one of two routes,
Parents who respond to the recruitment poster will be emailed the Patient Information Sheet and the Child Information Leaflet. A few days later, they will then be emailed to ask if they are interested in answering some questions to see if their child is eligible for the study. If they are, an appointment will be made to phone them and complete the screening questionnaire. For those children that fit the requirements for the trial, the parents will be invited for their child to take part. The participants recruited to the study will be allocated at random to either group A or B and will be given a unique Study Number. All data collected throughout the study will be anonymised and identified only by the participant's study number.
The first week of study will be a taste evaluation of the product for all participants (both groups). The taste evaluation is to ensure that the participant finds the taste acceptable and is willing to take the treatment product. For those that find the taste acceptable they will then either receive a 12-week course of Vivomixx probiotic or a 12-week course of the placebo powder, according to their random group allocation. The placebo powder has the same look and taste as Vivomixx.
Once the participant has passed the taste evaluation, the child's educator will be sent a letter inviting them to participate in the study. Included with this letter will be a consent slip, a copy of the Educator Questionnaire and a stamped addressed envelope for returning the questionnaires and consent slip to the researcher.
All participants' parents will be phoned by the researcher in Weeks 5 and 9 to adjust the treatment dose, offer support and check compliance.
Those parents whose child is eligible but who choose not to take part will be asked for the main reason and this will be logged in the screening log of patients.
After 12 weeks there will be 4 weeks when neither group is taking any treatment (a washout period). After this, participants who complete all 12 weeks of the double-blind treatment period will be eligible to enter the double-blind 12-week withdrawal period. The participants that have been taking the placebo will then receive a 12-week course of Vivomixx probiotic. The participants that have received Vivomixx, will take a 12-week course of the placebo. All participants' parents will be phoned by the researcher in Weeks 21 and 25 to adjust the treatment dose, offer support and check compliance. We will also ask about their experience of the study.
The investigators are primarily interested in whether participants in the intervention group (Vivomixx) have had more of an improvement in their overall function after their 12-week course of Vivomixx compared to that of the control group (receiving the placebo). The investigators will also measure the effect of the active treatment on parent stress compared to the control group and the effect of the active treatment on gastrointestinal symptoms and clinician's global assessment compared to the control group.
During the study the investigators will assess how well the participants kept to the treatment plan. The investigators will also record changes that happen during the trial that may affect the efficacy of treatment, for example taking antibiotics or a significant change in diet. The investigators will talk to the participant's parents to find how they perceived the treatment and how their child tolerated the treatment.
Statistical methodology and analysis The intention-to-treat (ITT) analysis will be performed on all participants who are randomised. An additional analysis will be done on only those participants who complete the study per protocol analysis. Details of the statistical analysis is given in the Statistical Analysis Plan.
1,030 studies on the registry are indexed under Autistic Disorder; 266 are open to participants now.
This study's enrollment of 69 is above the median of 49 across 811 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
Dietary Supplement: Vivomixx · Dietary Supplement: Placebo
This group starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
Dietary Supplement: Vivomixx · Dietary Supplement: Placebo
Drug pages: Streptococcus thermophilus · Bifidobacterium breve · Bifidobacterium animalis subsp. lactis · Lacteol · Lactobacillus plantarum · Lacticaseibacillus paracasei · Lactobacillus helveticus
Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
4.4 grams of maltose and silicon dioxide per sachet
A Change in the Autism Treatment Evaluation Checklist (ATEC) Total Score Compared to Baseline.
The ATEC is a one-page form, designed to be completed by parents, teachers, or caregivers. It consists of 4 subtests: I. Speech/Language Communication (14 items); II. Sociability (20 items); III. Sensory/ Cognitive Awareness (18 items); and IV. Health/Physical/Behavior (25 items). The scale covers 77 items and gives a total score and scores for each of the 4 sub-sections. The higher the score, the greater the impairment overall or in a sub-section. The ATEC total score can range from 0 - 180 and is calculated by summing the scores of each subsection.
Time frame: ATEC will be measured at the time of enrolment to the study, after the first 12-week treatment and after the second 12-week treatment by the child's primary carer and also by the child's educator.
The Change in the Frequency of Gastrointestinal Symptoms Compared to Baseline, as Measured by the Gastrointestinal History (GIH) Questionnaire.
In 2003 the Childhood Autism Risks from Genetics and the Environment (CHARGE) study developed and began using a frequency assessment of GI symptoms in autistic children, which they called the Gastrointestinal History Questionnaire. The Gastrointestinal History questionnaire (GIH) includes 10 Likert scale items for the following symptoms: abdominal pain, gaseousness/bloating sensation, diarrhoea, constipation, pain on stooling, vomiting, difficulty swallowing, blood in stools and blood in vomit. These have been equated to a numerical score as follows; never=0, rarely=1, sometimes=2, frequently=3, always=4.
Time frame: GIH will be measured at the time of enrolment to the study, after the first 12-week treatment and after the second 12-week treatment.
A Change in the Aberrant Behaviour Checklist (ABC) Section Scores Compared to Baseline.
Maladaptive behavior will be measured using five subscales of the ABC: Irritability (15 items), Lethargy/social withdrawal (16 items), Stereotypic behaviour (7 items), Hyperactivity/Noncompliance (16 items) and Inappropriate speech (4 items). A higher score indicates greater difficulty. The minimum score for each section is 0. The maximum scores for the sections are: Irritability 45, Lethargy/social withdrawal 48, Stereotypic behaviour 21, Hyperactivity/Noncompliance 48 and Inappropriate speech 12.
Time frame: ABC was measured at the time of enrolment to the study, after the first 12-week treatment and after the second 12-week treatment by the child's primary carer.
The Change in the Autism Parenting Stress Index (APSI) Score Compared to Baseline.
This one-page, self-assessment questionnaire was developed and validated in 2012. It is designed to assess parent stress in 13 aspects of autism of concern to parents and to provide a measure of parenting stress specific to core symptoms of autism and common co-occurring issues. It reflects the time, effort and actual difficulty of parenting in the light of the physical, social and communication barriers imposed by autism. It is intended for use by clinicians to assess the effects of an intervention on parenting stress. A higher score indicates greater parenting stress. The minimum score is 0 and the maximum score is 65.
Time frame: APSI will be measured at the time of enrolment to the study, after the first 12-week treatment and after the second 12-week treatment.
| Milestone | Vivomixx, Then Placebo | Placebo, Then Vivomixx |
|---|---|---|
| Started | 35 | 34 |
| Taste test (1 week) | 35 | 34 |
| Part 1 treatment (12 weeks) | 34 | 34 |
| Washout (4 weeks) | 34 | 32 |
| Part 2 treatment (12 weeks) | 34 | 32 |
| Completed | 31 | 27 |
| Not completed | 4 | 7 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Protocol violation | 1 | 1 |
The ATEC is a one-page form, designed to be completed by parents, teachers, or caregivers. It consists of 4 subtests: I. Speech/Language Communication (14 items); II. Sociability (20 items); III. Sensory/ Cognitive Awareness (18 items); and IV. Health/Physical/Behavior (25 items). The scale covers 77 items and gives a total score and scores for each of the 4 sub-sections. The higher the score, the greater the impairment overall or in a sub-section. The ATEC total score can range from 0 - 180 and is calculated by summing the scores of each subsection.
| percentage change from baseline score | Vivomixx | Placebo |
|---|---|---|
| A Change in the Autism Treatment Evaluation Checklist (ATEC) Total Score Compared to Baseline. | -12.122 ± 20.9140 | -11.427 ± 20.3055 |
In 2003 the Childhood Autism Risks from Genetics and the Environment (CHARGE) study developed and began using a frequency assessment of GI symptoms in autistic children, which they called the Gastrointestinal History Questionnaire. The Gastrointestinal History questionnaire (GIH) includes 10 Likert scale items for the following symptoms: abdominal pain, gaseousness/bloating sensation, diarrhoea, constipation, pain on stooling, vomiting, difficulty swallowing, blood in stools and blood in vomit. These have been equated to a numerical score as follows; never=0, rarely=1, sometimes=2, frequently=3, always=4.
| units on a scale | Vivomixx | Placebo |
|---|---|---|
| Change in abdominal pain frequency | -0.92 ± 0.128 | -0.82 ± 0.128 |
| Change in gaseousness frequency | -0.70 ± 0.159 | -0.86 ± 0.157 |
| Change in diarrhoea frequency | -0.92 ± 0.149 | -0.80 ± 0.153 |
| Change in constipation frequency | -0.92 ± 0.176 | -1.00 ± 0.153 |
| Change in pain on stooling frequency | -0.92 ± 0.158 | -0.82 ± 0.160 |
| Change in difficulty swallowing frequency | -0.12 ± 0.063 | -0.08 ± 0.084 |
| Change in vomiting frequency | -0.27 ± 0.095 | -0.23 ± 0.094 |
| Change in blood in stool frequency | -0.06 ± 0.048 | -0.06 ± 0.043 |
| Change in blood in vomit frequency | -0.02 ± 0.015 | -0.02 ± 0.015 |
Maladaptive behavior will be measured using five subscales of the ABC: Irritability (15 items), Lethargy/social withdrawal (16 items), Stereotypic behaviour (7 items), Hyperactivity/Noncompliance (16 items) and Inappropriate speech (4 items). A higher score indicates greater difficulty. The minimum score for each section is 0. The maximum scores for the sections are: Irritability 45, Lethargy/social withdrawal 48, Stereotypic behaviour 21, Hyperactivity/Noncompliance 48 and Inappropriate speech 12.
| score on a scale | Vivomixx | Placebo |
|---|---|---|
| Change in Irritability | -3.00 ± 1.100 | -3.05 ± 1.065 |
| Change in Lethargy/social withdrawal | -2.26 ± 0.842 | -3.11 ± .780 |
| Change in stereotypic behaviour | -1.06 ± 0.404 | -1.08 ± 0.399 |
| Change in Hyperactivity/Noncompliance | -2.42 ± 0.944 | -2.16 ± 0.894 |
| Change in Inappropriate speech | -0.45 ± 0.290 | -0.37 ± 0.316 |
This one-page, self-assessment questionnaire was developed and validated in 2012. It is designed to assess parent stress in 13 aspects of autism of concern to parents and to provide a measure of parenting stress specific to core symptoms of autism and common co-occurring issues. It reflects the time, effort and actual difficulty of parenting in the light of the physical, social and communication barriers imposed by autism. It is intended for use by clinicians to assess the effects of an intervention on parenting stress. A higher score indicates greater parenting stress. The minimum score is 0 and the maximum score is 65.
| difference in score on a scale from base | Vivomixx | Placebo |
|---|---|---|
| The Change in the Autism Parenting Stress Index (APSI) Score Compared to Baseline. | -3.73 ± 0.928 | -3.11 ± 0.872 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vivomixx | 0/66 (0%) | 0/66 (0%) | 10/66 (15.2%) |
| Placebo | 0/68 (0%) | 0/68 (0%) | 16/68 (23.5%) |
| Event | Vivomixx | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/66 | 5/68 |
| Loose stoolsGastrointestinal disorders | 3/66 | 1/68 |
| Worsening behaviourGeneral disorders | 2/66 | 3/68 |
| Faecal incontinenceGastrointestinal disorders | 2/66 | 3/68 |
| SeizureNervous system disorders | 1/66 | 0/68 |
| Temporary poor sleepGeneral disorders | 1/66 | 0/68 |
| Food intolerance reactionImmune system disorders | 0/66 | 1/68 |
| Persistent coughRespiratory, thoracic and mediastinal disorders | 0/66 | 1/68 |
| Panic attackPsychiatric disorders | 0/66 | 1/68 |
| Increased sensory sensitivityNervous system disorders | 0/66 | 1/68 |
| Age, Continuous(years) | Vivomixx, Then Placebo | Placebo, Then Vivomixx | Total |
|---|---|---|---|
| Mean age | 8.3 ± 2.3 | 7.3 ± 2.9 | 7.8 ± 2.6 |
| Sex: Female, Male(Participants) | Vivomixx, Then Placebo | Placebo, Then Vivomixx | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 31 | 26 | 57 |
| Race/Ethnicity, Customized(Participants) | Vivomixx, Then Placebo | Placebo, Then Vivomixx | Total |
|---|---|---|---|
| Ethnic origin — Arab | 1 | 1 | 2 |
| Ethnic origin — Asian/Asian British | 3 | 3 | 6 |
| Ethnic origin — Black/African/Caribbean/Black British | 2 | 2 | 4 |
| Ethnic origin — Chinese | 0 | 1 | 1 |
| Ethnic origin — Hispanic | 0 | 1 | 1 |
| Ethnic origin — Mixed/Multiple ethnic | 8 | 4 | 12 |
| Ethnic origin — White | 21 | 22 | 43 |
| Autism Treatment Evaluation Checklist Total score(score on a scale) | Vivomixx, Then Placebo | Placebo, Then Vivomixx | Total |
|---|---|---|---|
| Mean | 70.15 ± 25.28 | 76.32 ± 30.18 | 73.24 ± 27.80 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Streptococcus thermophilus · Bifidobacterium breve · Bifidobacterium animalis subsp. lactis · Lacteol · Lactobacillus plantarum · Lacticaseibacillus paracasei · Lactobacillus helveticus